About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Sigyn Therapeutics to be Featured in Fireside Chat With Zacks Healthcare Analyst

The Exclusive Event Kicks-Off Tomorrow February 26th at 4pm Eastern   

The Fireside Chat will review the emergence of blood purification therapies to address life-threatening infectious disease conditions that are beyond the reach of drugs and additionally will discuss the development of devices to synergistically optimize the benefit of leading drugs to treat cancer.

Event Details

Date: February 26th

Time: 4pm Eastern (1pm Pacific)

Registration: https://forcefamilyoffice.com/events/healthcare/sigyn-therapeutics-coming-february-26-2025/

Force Family Office Event Description

Healthcare is driven by innovation. New discoveries, technologies, applications, molecules, devices, and formulations are at the heart of an industry that never stands still. Which are the experts watching?  One of those is Sigyn Therapy, a blood purification therapy with applications in infectious disease, oncology, dialysis and organ transplantation.  Register now to join this Fireside Chat with Zacks Senior Healthcare Analyst, John Vandermosten, and Jim Joyce, CEO of Sigyn Therapeutics, for a discussion of innovations on the horizon that will be creating value in the healthcare sector.

About Sigyn Therapeutics(TM)

Sigyn Therapeutics is developing next-generation blood purification therapies to address cancer and life-threatening infectious disease disorders that are not treatable with drugs.  The Company’s lead product candidate, Sigyn Therapy(TM) has been demonstrated to reduce the presence of viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. Based on these capabilities, Sigyn Therapy(TM) is a candidate to treat life-threatening viral pathogens, antibiotic-resistant bacterial infections, endotoxemia, and sepsis, which is the leading cause of death in U.S. hospitals.  The clinical protocol of first-in-human studies incorporates Sigyn Therapy with regularly scheduled dialysis treatments to address endotoxemia and concurrent inflammation, which are highly prevalent disorders that shorten the lives of end-stage renal disease (ESRD) patients. Extending the lives of those with ESRD could significantly impact dialysis industry revenues. 

The Company’s oncology pipeline is comprised of ImmunePrep(TM), a platform to enhance the delivery of immunotherapeutic antibodies; ChemoPrep(TM) to improve the delivery of chemotherapeutic agents; and ChemoPure(TM) to reduce chemotherapy toxicity.  If successfully advanced, the Company’s therapies offer to provide strategic value to the dialysis and biopharmaceutical industry.

To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com

CONTACTS:
Sigyn Therapeutics, Inc.
Johan Louw
Senior Vice President of Strategic Programs
281.660.1815  
jlouw@SigynTherapeutics.com

Jim Joyce
CEO, Inventor
Email: jj@SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.27
+5.79 (2.67%)
AAPL  263.70
+1.46 (0.56%)
AMD  239.75
-0.81 (-0.34%)
BAC  51.91
-0.13 (-0.25%)
GOOG  249.41
-7.61 (-2.96%)
META  733.95
+1.78 (0.24%)
MSFT  515.86
-0.93 (-0.18%)
NVDA  182.46
-0.18 (-0.10%)
ORCL  279.49
+2.31 (0.83%)
TSLA  447.56
+0.13 (0.03%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.